Jacob Paul Smeltzer, MD

As a native of Kansas, I am excited to be returning home and joining Saint Luke’s Cancer Institute. Most recently I have served as chief fellow and instructor in oncology while completing my training in hematology and oncology at the Mayo Clinic. My clinical interests are in hematological malignancies, primarily lymphoma and myeloma; genitourinary cancers such as prostate, bladder, and renal cell; as well as general oncology. My research interests have been primarily in Non-Hodgkin Lymphoma where I have published and presented on both basic science and clinical research. I am committed to providing comprehensive cancer care to the whole person. 

 

Smeltzer JP, Jones JM, Ziesmer S et al. Pattern of CD14+ follicular dendritic cells and D1+ cells independently predicts rate of transformation in follicular lymphoma. Clinical Cancer Research 20(11):2862-72, 2014.

 

Jackson, AE, Smeltzer JP, Habermann TM et al. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. American Journal Hematology 2014.

 

Smeltzer JP, Howard M, Gonsalves W and Witzig TW. Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab. Case Reports Hematology (2014):641483, 2014.

 

El-Haj N, Gonsalves WI, Gupta V, Smeltzer JP, Parikh SA, Singh PP, Gangat N.

Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia. Case Reports Hematology. (2014):287479, 2014.

 

Gonsalves WI, He R, Pardanani A, Gupta V, Smeltzer JP, Hanson CA, Witzig TE. Chronic Eosinophilia Leukemia-NOS in the background of a large cell lymphoma. Case Reports Hematology (2013):458303, 2013. 

 

Gonsalves WI, Gupta V, Smeltzer JP, Singh PP, McWilliams RR, Gangat N. Gallbladder cancer associated thrombotic microangiopathy. Future Oncology. 9(11):1711-5, 2013.

 

Smeltzer JP, Viswanatha DS, Habermann TM, et al. Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic lymphoma on vorinostat. American Journal Hematology 87(9):927-28, 2012.

 

Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic Significance of PET imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation” Biology Blood Marrow Transplant. 17(11):1646-52, 2011.

 

Smeltzer JP, Silberstein PT, and Lynch HT. Personalized chemotherapy for BRCA1 mutation positive patients. Hereditary Cancer in Clinical Practice 5:138-140, 2007.

 

 

Smeltzer JP et al. Pattern of CD14+ follicular dendritic cells and D1+ cells independently predicts rate of transformation in follicular lymphoma. Poster Discussion presentation at American Society of Oncology (ASCO) annual meeting Chicago, June 2013. 

 

Smeltzer JP et al. Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma. Oral presentation at American Society for Blood and Marrow Transplantation (ASBMT) annual meeting, Salt Lake City, February 2013. 

 

Smeltzer JP et al. Long term clinical outcomes in patients with massive splenomegaly and Non-Hodgkin Lymphoma treated with splenectomy. Poster presented at American Society of Hematology (ASH) annual meeting. Atlanta, December 2012.

 

Smeltzer JP et al. Prognostic Significance of PET imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation, Poster presented at American Society of Hematology (ASH) annual meeting, New Orleans, December 2009.